Jatin Shah - 07 Feb 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Medical Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Jatin Shah
Issuer symbol
KPTI
Transactions as of
07 Feb 2022
Net transactions value
-$16,805
Form type
4
Filing time
09 Feb 2022, 16:27:50 UTC
Previous filing
13 Jul 2021
Next filing
22 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $16,805 -1,704 -1.3% $9.86* 130,756 07 Feb 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
F3 Includes 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021.